FDA Approves Mavyret (glecaprevir/pibrentasvir) Treatment Duration of Eight Weeks for Treatment-Na ïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Mavyret (glecaprevir/pibrentasvir)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news